BIO Suggests Update to WHO's Naming Policy for Biological Products
13th Nov 2006, 22:53 GMT
Biotech Industry Organization President and CEO Jim Greenwood issued the following statement regarding the WHO's program on the selection of Int'l Nonproprietary Names: Today, BIO presented its recommendations to the WHO to assign a distinct nonproprietary name to each unique biological product, including follow-on biologics.
BIO Suggests Update to WHO's Naming Policy for Biological Products related news:
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems — ArriveNet : Health
- HSE adopts naming rights policy — IndyStar.com - Top Stories
- Bio-Rad Laboratories: Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems — Market Wire - Medical and Healthcare
- avVaa World Health Care Products Signs New Spokesman — Bio-Technology News from StratCenter.com
- Citigroup Buys Naming Rights to Mets' Park — WSJ.com: What's News US
- Ciphergen Completes Sale of Life Science Research Business to Bio-Rad Labs — StratWire - Business of Healthcare NewsFeed
- CLC bio Expands Product Line with Kapelan's 1D Gel Analysis Software — PressReleaseNetwork.com: News Feed
- Bio-Rad buys ProteinChip and Seldi from Ciphergen — DNA sequencing and synthesis latest news on Laboratorytalk
- Cisco Buys Naming Rights to A's Park — WSJ.com: What's News US
- A's unveil $120M naming rights deal with Cisco — bizjournals.com Sports Business:General headlines
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress